Lipids and Metabolic

heartwire News

  • HOPE-3: No Effect of CVD Drugs on Erectile Function A prespecified analysis of the large HOPE-3 trial finds neither help nor harm on erectile function from cardiovascular drugs, including statins or the antihypertensive combination of candesartan plus low-dose thiazide.
  • Women Have Particular Stroke Risk Factors, Outcomes Women face different risk factors for stroke and experience worse outcomes after stroke, compared with men, according to four related articles in a focused update online February 8 in the journal Stroke.
  • Could Money Spent on Diabetes Medications Pay for Surgery? Those with obesity are more likely to stop taking glucose-lowering medication for diabetes 6 years after bariatric surgery than controls. Could money earmarked for drugs be redirected to pay for operations?
  • Genetic Score May Best FH Variant for Predicting Early-Onset CAD The challenge now is 'more about whether clinicians and patients armed with this additional information are able to make decisions that produce fewer events,' experts say.


  • Patient Transition to Dialysis: Advice to Providers   Dr Szczech discusses the emotional challenges that patients with CKD face in their transition to dialysis, and offers suggestions to PCPs and pharmacists who see these patients.
  • Heart Defibrillators in CKD: More Harm Than Good? Dr Bansal comments on her study on heart defibrillators in patients with kidney disease and the greater risk for hospitalization for heart failure.
  • Drug Safety Warnings and Updates: October-December 2017 Don't miss these important summaries of safety labeling changes and boxed warnings by the FDA for the fourth quarter of 2017.
  • 7 Cardiology Trials to Look for in 2018   Trials on PCSK9 inhibitors, antiplatelets, anticoagulants, and even catheter ablation of atrial fibrillation are among Drs Harrington and Gibson's picks for what to look for in 2018.